Stemline Therapeutics Inc (STML) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access STML Annual Balance Sheets →
Observing balance sheet movements over recent quarters helps explain how Stemline Therapeutics Inc adapts its asset base and funding mix.
Quarterly Report, GAAP in USD millions
ITEM
(Mar 31 2020)
(Dec 31 2019) (Sep 30 2019) (Jun 30 2019) (Mar 31 2019)
Assets
Cash & cash equivalent29.23
Short-term Investments, Total122.29
Cash & Short-term Investments151.00
Accounts receivable11.88
Inventories1.39
Prepaid Expense And Other Assets Current4.28
Total Current Assets169.07
Equipment/Property/Plant Net0.19
Other Assets, Noncurrent1.00
Operating Lease Right Of Use Asset0.00
Total Assets170.61
Liabilities
Accounts Payable and Accrued Liabilities, Current LI21.84
Other Liabilities, Current0.92
Total Current Liabilities22.76
Total Long-term Debt0.00
Other liabilities, Noncurrent0.21
Operating Lease Liability Current0.00
Operating Lease Liability Noncurrent0.00
Total Liabilities22.96
Stockholders' Equity
Common Stock Value0.01
Additional Paid In Capital Common Stock534.24
Retained Earnings / Accumulated Deficit-387.20
Other Equity0.60
Common Stockholder's Equity147.65
Total Stockholder's Equity147.65
Liabilities & Stockholder's Equity170.61
4 historic quarters locked

Sign in to unlock the full Stemline Therapeutics Inc balance sheet history.

About STML Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-Q filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

  • Form: 10-Q
  • Filed with the SEC: n/a

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.